Clinical results have shown that myCAFs have a synergistic effect on T cells and inhibit tumor growth, while inflammatory CAFs promote tumor growth and immunosuppressive response by secreting ECM proteins and cytokines such as IL-6, IL-11 and leukemia suppressors (88). The gene discussed is IL11; the disease is neoplasm.